Loading
A phase 1/2 trial of Pembrolizumab, Ipilimumab, Nivolumab in non-small-cell lung cancer and small-cell lung cancer, run by Vyriad, Inc., active and no longer recruiting.
Ph I/II Trial of Systemic VSV-IFNβ-NIS in Combination With Checkpoint Inhibitor Therapy in Patients With Select Solid Tumors is a phase 1/2 interventional study registered as NCT03647163 by Vyriad, Inc., with 33 participants enrolled, started 2019-04-09 and due to reach its primary completion in 2025-07-31. Interventions recorded: VSV-IFNβ-NIS, Pembrolizumab, ipilimumab + nivolumab. Conditions listed: Solid Tumor, Non Small Cell Lung Cancer, Neuroendocrine Carcinoma, Renal Cell Carcinoma (RCC). No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Ipilimumab, Renal cell carcinoma, Nivolumab.
Shares Ipilimumab, Nivolumab, Pembrolizumab.
Shares Ipilimumab, Renal cell carcinoma, Nivolumab.
Shares Ipilimumab, Renal cell carcinoma, Nivolumab.
Shares Ipilimumab, Renal cell carcinoma, Nivolumab, Pembrolizumab.
Shares Ipilimumab, Nivolumab, Small-cell lung cancer, Non-small-cell lung cancer.
Shares Ipilimumab, Nivolumab, Non-small-cell lung cancer.
Shares Ipilimumab, Nivolumab, Non-small-cell lung cancer.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/